---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001500"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T10:35:37.008006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teva Q3 revenue falls 8% to $3.6B; non-GAAP EPS $0.59 flat; opioid settlement progress

## Summary
- Revenue $3.595B (-8% YoY, -2% in local currency); GAAP EPS $0.05; non-GAAP EPS $0.59 (flat YoY).
- 2022 revenue guidance cut to $14.8-15.4B (prev $15.0-15.6B) due to FX; all other guidance affirmed.
- Opioid litigation: substantial progress toward nationwide settlement; agreement in principle with NY AG; reserve updated.
- AUSTEDO U.S. revenue +30% YoY, on track for ~$1B annual; AJOVY gains share in U.S., Europe, Japan.
- Cash from operations $543M; free cash flow $685M; non-GAAP tax rate outlook revised to 12-14%.

## SEC filing metadata
- accession: 0001157523-22-001500
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/0001157523-22-001500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/a52958636.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001500
- JSON: https://secwatch.observer/filing/0001157523-22-001500.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001500.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2022 results: revenue $3,595 million, net income GAAP diluted EPS of $0.05, EPS Non-GAAP diluted EPS of $0.59. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2022
  - Revenue: $3,595 million
  - Net income: GAAP diluted EPS of $0.05
  - EPS: Non-GAAP diluted EPS of $0.59
  - Guidance: reaffirmed
  - Result: reported results
  source text: (EXHIBIT 99.1) --- EX-99.1 2 a52958636ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Teva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $543 million Free cash flow of $685 million 2022 revenues outlook revised
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752322001500/0001157523-22-001500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.